Life Sciences

Evgen Pharma

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The company is carrying out pre-clinical work in multiple sclerosis and has a clinical interest in prostate cancer.

Evgen Pharma’s objective is to become the leading company in the development of pharmaceuticals that activate the antioxidant response element, Nrf2. Evgen Pharma’s core technology is Sulforadex®, a means of synthesising and concurrently stabilising the naturally occurring compound sulforaphane (or novel analogues based upon sulforaphane).

Market: AIM

Ticker: EVG

evgen.com

Lead analyst: Dr Martin Hall